idx899
Small moleculeexperimental
Clinical trial activity
12 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00920088)
Timeline
Indications
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2248761 compound
- gsk2248761
- gsk2248761
- gsk2248761
- gsk 2248761
- gsk-2248761
- idx12899
- idx 12899
- idx-12899
- idx899
- idx 899
- idx-899
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01458132 | N/A | Jul 29, 2011 | GlaxoSmithKline, ViiV Healthcare |
| NCT01283100 | Phase 1 | Mar 1, 2011 | GlaxoSmithKline, ViiV Healthcare |
| NCT01273103 | Phase 1 | Jan 1, 2011 | GlaxoSmithKline, ViiV Healthcare |
| NCT01231555 | Phase 2 | Nov 1, 2010 | GlaxoSmithKline, ViiV Healthcare |
| NCT01199731 | Phase 2 | Oct 1, 2010 | GlaxoSmithKline, ViiV Healthcare |
| NCT01209117 | Phase 1 | Sep 1, 2010 | GlaxoSmithKline, ViiV Healthcare |
| NCT01195974 | Phase 1 | Sep 1, 2010 | GlaxoSmithKline, ViiV Healthcare |
| NCT01138072 | Phase 1 | Jun 1, 2010 | GlaxoSmithKline |
| NCT01101893 | Phase 1 | Apr 1, 2010 | GlaxoSmithKline, ViiV Healthcare |
| NCT01031472 | Phase 1 | Dec 1, 2009 | GlaxoSmithKline |
| NCT00945282 | Phase 2 | Oct 1, 2009 | GlaxoSmithKline, ViiV Healthcare |
| NCT00920088 | Phase 1 | Jun 1, 2009 | GlaxoSmithKline |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 12 | 4 | 3 | 2009 |
| ViiV Healthcare | For profit | 9 | 8 | 3 | 2009 |
2 organizations
Page 1 / 1